Study Protocol
Published on 11 Nov 2025
Effect of angiotensin II receptor blockers on efficacy and safety of Camrelizumab plus chemotherapy in the first-line therapy for advanced non-small cell lung cancer (ARMOR I): a protocol for a prospective, real-world, multicenter, intervention clinical trial
in Cancer Immunity and Immunotherapy
- 382 views